Zymeworks Inc (ZYME):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zymeworks Inc (ZYME) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8038
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zymeworks Inc (Zymeworks) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Its pipeline products include ZW25 and ZW49, novel bispecific antibodies used for the removal of HER2 protein from the cell surface in patients with gastric, breast, and ovarian cancers. Zymeworks’ proprietary therapeutic platforms and its fully-integrated drug development engine ZymeCAD, provide the compatibility to engineer and develop highly-differentiated protein-based drugs candidates.The company is developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. The company has operations in Canada and the US. Zymeworks is headquartered in Vancouver, British Columbia, Canada.

Zymeworks Inc (ZYME) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zymeworks Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Zymeworks Raises USD61.5 Million in Series A Financing 12
Zymeworks Secures USD23.98 Million in Venture Funding 14
Zymeworks Raises USD4 Million in Venture Financing 15
Zymeworks Raises US$11 Million In Venture Financing 16
Partnerships 17
ImClone Systems Enters Licensing Agreement with Zymeworks 17
Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18
Applied BioMath Extends Partnership with Zymeworks 19
Zymeworks Enters into Agreement with Kairos Therapeutics 20
ProBioGen Enters into Agreement with Zymeworks 21
Zymeworks Enters into Research Agreement with University of California, Los Angeles 22
National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 23
Licensing Agreements 24
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 24
Janssen Biotech Enters into Licensing Agreement with Zymeworks 25
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 26
Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 27
Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 28
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 29
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 30
Zymeworks Enters into Licensing Agreement with Selexis 31
Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 32
Zymeworks Extends Licensing Agreement with Merck 33
Zymeworks Expands Licensing Agreement with Eli Lilly 34
Zymeworks Enters into Licensing with Agreement with Lilly 35
Equity Offering 36
Zymeworks Raises USD97.8 Million in Public Offering of Share 36
Zymeworks Announces Underwriters Exercise of Over-Allotment Option in IPO 38
Zymeworks Raises USD1.8 Million in Private Placement of Shares 40
Zymeworks Raises USD8.6 Million in Private Placement of Shares 41
Zymeworks Completes Private Placement of Shares for USD17.3 Million 42
Acquisition 43
Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 43
Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 44
Zymeworks Inc – Key Competitors 45
Zymeworks Inc – Key Employees 46
Zymeworks Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Aug 01, 2018: Zymeworks reports financial results for the second quarter of 2018 48
May 01, 2018: Zymeworks Reports 2018 First Quarter Financial Results 50
Mar 14, 2018: Zymeworks Reports 2017 Year-End Financial Results 51
Nov 08, 2017: Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update 52
Aug 08, 2017: Zymeworks Reports Second Quarter 2017 Financial Results 53
May 15, 2017: Zymeworks Reports First Quarter 2017 Financial Results 54
Corporate Communications 55
Sep 19, 2018: Zymeworks appoints Anthony Polverino as executive vice president of early development and Chief Scientific Officer 55
Jun 07, 2018: Zymeworks appoints Ali Tehrani and Nick Bedford as board directors 56
Feb 14, 2017: Zymeworks Appoints Dr. Kenneth Hillan and Hollings Renton to its Board of Directors 57
Product News 58
Jan 05, 2017: Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration 58
Clinical Trials 59
Mar 14, 2018: Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Zymeworks Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zymeworks Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zymeworks Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zymeworks Raises USD61.5 Million in Series A Financing 12
Zymeworks Secures USD23.98 Million in Venture Funding 14
Zymeworks Raises USD4 Million in Venture Financing 15
Zymeworks Raises US$11 Million In Venture Financing 16
ImClone Systems Enters Licensing Agreement with Zymeworks 17
Zymeworks Enters into Research Agreement with University of Victoria and BC Cancer Agency 18
Applied BioMath Extends Partnership with Zymeworks 19
Zymeworks Enters into Agreement with Kairos Therapeutics 20
ProBioGen Enters into Agreement with Zymeworks 21
Zymeworks Enters into Research Agreement with University of California, Los Angeles 22
National Research Council Enters into Co-Development Agreement with Zymeworks for Cancer 23
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 24
Janssen Biotech Enters into Licensing Agreement with Zymeworks 25
Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 26
Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 27
Zymeworks Enters into Licensing Agreement with Innovative Targeting Solutions 28
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 29
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 30
Zymeworks Enters into Licensing Agreement with Selexis 31
Celgene Exercises Licensing Agreement with Zymeworks for Bi-Specific Antibody 32
Zymeworks Extends Licensing Agreement with Merck 33
Zymeworks Expands Licensing Agreement with Eli Lilly 34
Zymeworks Enters into Licensing with Agreement with Lilly 35
Zymeworks Raises USD97.8 Million in Public Offering of Share 36
Zymeworks Announces Underwriters Exercise of Over-Allotment Option in IPO 38
Zymeworks Raises USD1.8 Million in Private Placement of Shares 40
Zymeworks Raises USD8.6 Million in Private Placement of Shares 41
Zymeworks Completes Private Placement of Shares for USD17.3 Million 42
Zymeworks Acquires Remaining 80.01% Stake in Kairos Therapeutics for USD24.8 Million 43
Zymeworks Acquires 19.99% Stake in Kairos Therapeutics for USD3.6 Million 44
Zymeworks Inc, Key Competitors 45
Zymeworks Inc, Key Employees 46
Zymeworks Inc, Subsidiaries 47

List of Figures
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zymeworks Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Zymeworks Inc (ZYME):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Recepta Biopharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Recepta Biopharma SA (Recepta) is a biotechnology company that offers research and development of drugs used in the treatment of cancer. The company offers antibodies and peptide products. It offers antibodies such as monoclonal antibody hu3s193 - anti-ley, monoclonal antibody 58-1066 - anti …
  • Parkland Fuel Corporation (PKI):石油・ガス:M&Aディール及び事業提携情報
    Summary Parkland Fuel Corp (Parkland) is a downstream energy company. It markets various fuel and petroleum products, including gasoline, propane, lubricants, diesel, heating oil, and other petroleum products. The company maintains a portfolio of supply relationships, storage infrastructure, and thi …
  • Credit Du Nord Sa:企業の戦略・SWOT・財務分析
    Credit Du Nord Sa - Strategy, SWOT and Corporate Finance Report Summary Credit Du Nord Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • Toppan Forms Co Ltd:企業の戦略・SWOT・財務分析
    Toppan Forms Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Toppan Forms Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Volta River Authority-エネルギー分野:企業M&A・提携分析
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. The authority produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. It procures energy from Takoradi International Company Ltd; an …
  • Sujana Universal Industries Ltd. (SUJANAUNI):企業の財務・戦略的SWOT分析
    Sujana Universal Industries Ltd. (SUJANAUNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • SJVN Ltd (SJVN):企業の財務・戦略的SWOT分析
    SJVN Ltd (SJVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Orchid Pharma Ltd (ORCHIDPHAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Orchid Pharma Ltd (Orchid), formerly Orchid Chemicals & Pharmaceuticals Ltd is a pharmaceutical company that develops and manufactures pharmaceutical solutions such as formulations and API products. The company offers formulations such as cardiovascular products, neuropsychiatry products, an …
  • Global Bioenergies SA (ALGBE):企業の財務・戦略的SWOT分析
    Global Bioenergies SA (ALGBE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • MonTa Biosciences ApS:製薬・医療:M&Aディール及び事業提携情報
    Summary MonTa Biosciences ApS (MonTa Biosciences) is a biotechnology company that develops and commercializes immuno-oncology therapeutics for cancer therapy. Its pipeline products include MBS2, and MBS5 used for the treatment of cancer and infectious diseases. The company’s technology is based on T …
  • BOE Technology Group Co Ltd:戦略・SWOT・企業財務分析
    BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Reins International Inc.:企業の戦略・SWOT・財務分析
    Reins International Inc. - Strategy, SWOT and Corporate Finance Report Summary Reins International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vision RT Ltd:企業の戦略的SWOT分析
    Vision RT Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Vivakor Inc (VIVK):石油・ガス:M&Aディール及び事業提携情報
    Summary Vivakor Inc (Vivakor) is a technology and asset acquisition company that creates, acquires and accumulates distinct assets, intellectual properties, and various technologies. The company concentrates on precious metals extraction in the US. It also concentrates on oil extraction from shallow …
  • Duke Energy Corporation (DUK)-エネルギー分野:企業M&A・提携分析
    Summary Duke Energy Corporation (Duke Energy) is an integrated energy utility that undertakes the generation, transmission, distribution and sale of electricity; transportation and sale of natural gas; and provision of related energy services in the Southeast and Midwest regions of the US. It also p …
  • WIV Wein International AG:企業の戦略・SWOT・財務分析
    WIV Wein International AG - Strategy, SWOT and Corporate Finance Report Summary WIV Wein International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ContraVir Pharmaceuticals Inc (CTRV)-製薬・医療分野:企業M&A・提携分析
    Summary ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that focusses on development and commercialization of targeted antiviral therapies. The company’s pipeline product includes TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its …
  • Schroders Plc
    Schroders Plc - Strategy, SWOT and Corporate Finance Report Summary Schroders Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆